These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38985885)

  • 1. Cardiovascular safety of pimitespib in patients with advanced solid tumors: An open-label, nonrandomized, phase 1 study.
    Naoki K; Igawa S; Uojima H; Tsumura H; Sengoku N; Karayama M; Shimomura A; Ohtake T; Shio Y; Hosokawa A; Komatsu Y; Kumagai Y
    Cancer; 2024 Nov; 130(21):3745-3756. PubMed ID: 38985885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial.
    Kurokawa Y; Honma Y; Sawaki A; Naito Y; Iwagami S; Komatsu Y; Takahashi T; Nishida T; Doi T
    Ann Oncol; 2022 Sep; 33(9):959-967. PubMed ID: 35688358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors.
    Doi T; Yamamoto N; Ohkubo S
    Future Oncol; 2024 Mar; 20(9):507-519. PubMed ID: 38050698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors.
    Patel C; Goel S; Patel MR; Rangachari L; Wilbur JD; Shou Y; Venkatakrishnan K; Lockhart AC
    Clin Pharmacol Drug Dev; 2020 Oct; 9(7):876-888. PubMed ID: 32488989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
    Olszanski AJ; Smith DC; Camacho LH; Thompson J; Ramalingam SS; Harvey RD; Campos L; Ferry D; Tang S; Gao L; Safran H
    Oncologist; 2016 Apr; 21(4):402-3. PubMed ID: 26984445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.
    Molife LR; Rudman SM; Alam S; Tan DS; Kristeleit H; Middleton G; Propper D; Bent L; Stopfer P; Uttenreuther-Fischer M; Wallenstein G; de Bono J; Spicer J
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1213-22. PubMed ID: 24085260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
    Zhang L; Li S; Zhang Y; Zhan J; Zou BY; Smith R; Martin PD; Jiang Y; Liao H; Guan Z
    Clin Ther; 2011 Mar; 33(3):315-27. PubMed ID: 21600385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.
    Bendell JC; Patel MR; Yoshida K; Seraj J; Weaver R; Lemech C; Todaro TG; Pant S; Arkenau HT
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1275-83. PubMed ID: 27151157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.
    Någård M; Ah-See ML; Strauss J; Wise-Draper T; Safran HP; Nadeau L; Edenfield WJ; Lewis LD; Rekić D; Dota C; Ottesen LH; Li Y; Mugundu GM
    Cancer Chemother Pharmacol; 2023 Aug; 92(2):141-150. PubMed ID: 37368100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.
    Chen N; Chawla SP; Chiorean EG; Read WL; Gorbaty M; Mita AC; Yung L; Bryan P; McNally R; Renschler MF; Sharma S
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):1083-94. PubMed ID: 23400695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
    Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors.
    Smith DC; Powderly J; Lee JJ; Shepard DR; Wallin J; Chaudhary A; Chao GY; Ng WT; Mitchell MI; Grau G; Kurek R; LoRusso P
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):271-80. PubMed ID: 27312733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors.
    Maison-Blanche P; Dakhil S; Baron A; Rottey S; Millard F; Daugaard G; Machiels JP; Conkright W; Sharma S; Soetekouw PM; Yachnin J; Sengeløv L; Van Veldhuizen P; Agarwala SS; Sémiond D; Chadjaa M; Shen L; Wade JL
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1241-52. PubMed ID: 24718982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.
    Jones RL; Bendell JC; Smith DC; Diefenbach K; Lettieri J; Boix O; Lockhart AC; O'Bryant C; Moore KN
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):777-84. PubMed ID: 26281907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
    Zhang W; Smulders R; Abeyratne A; Dietz A; Krauwinkel W; Kadokura T; Keirns J
    Clin Ther; 2013 Aug; 35(8):1150-1161.e3. PubMed ID: 23910665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes.
    Böttcher M; Düngen HD; Corcea V; Donath F; Fuhr R; Gal P; Mikus G; Trenk D; Coenen M; Pires PV; Maschke C; Aliprantis AO; Besche N; Becker C
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):145-155. PubMed ID: 36633816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.
    Fudio S; Tabernero J; Subbiah V; Chawla SP; Moreno V; Longo F; Lopez R; Anton A; Trigo JM; Shapiro G; Jeong W; Villalobos VM; Lubomirov R; Fernandez-Teruel C; Alfaro V; Boni V
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):113-124. PubMed ID: 33108504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors.
    Komatsu Y; Shimokawa T; Akiyoshi K; Karayama M; Shimomura A; Kawamoto Y; Yuki S; Tambo Y; Kasahara K
    Invest New Drugs; 2022 Oct; 40(5):1011-1020. PubMed ID: 35932386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors.
    Zhou X; Richardson DL; Dowlati A; Goel S; Sahebjam S; Strauss J; Chawla S; Wang D; Mould DR; Samnotra V; Faller DV; Venkatakrishnan K; Gupta N
    Clin Pharmacol Drug Dev; 2023 Mar; 12(3):257-266. PubMed ID: 36382849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.